HIV/AIDS Clinical Care: Meetings

Early ART Initiation Improves Survival in Resource-Limited Settings

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

New findings from Haiti (described at IAS 2009) support starting ART when CD4 counts fall below 350 cells/mm³ — the same threshold that is recommended in resource-rich settings.

• By Gerald H. Friedland, MD
• August 31, 2009

Report from the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

Our physician-editors detail the most important findings from this year's meeting

• By ACC Editors
• August 31, 2009

Report from the XVIII International HIV Drug Resistance Workshop

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

An expert's take on the most clinically relevant reports from this year's resistance meeting

• By Daniel R. Kuritzkes, MD
• August 24, 2009

SWITCHMRK: An Avoidable Raltegravir Disaster

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Somewhat predictably, treatment-experienced patients on stable regimens who switched from lopinavir/r to raltegravir did not fare as well as those who remained on lopinavir/r.

• By Helmut Albrecht, MD
• March 9, 2009

Timing of ART Initiation — Still No Definitive Answers

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Data from two observational studies presented at CROI 2009 are informative but not conclusive. However, both studies point to starting therapy at least before the CD4 count falls below 350 cells/mm³.

• By Charles B. Hicks, MD
• March 9, 2009

No Clinical Benefit from Adding IL-2 to ART

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

In two large trials presented at CROI 2009, CD4-cell increases were greater with IL-2 and ART together than with ART alone, but these increases did not lead to reductions in morbidity or mortality.

• By Keith Henry, MD
• March 9, 2009

First (Sort of) Positive Anti-HIV Microbicide Trial

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

Promising results from HPTN 035, a phase II trial of two microbicides, were reported at the 2009 Retrovirus Conference.

• By Carlos del Rio, MD
• March 9, 2009

Investigational Pharmacologic Boosters

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Two promising alternatives to ritonavir were described at this year’s Retrovirus Conference.

• By Charles B. Hicks, MD
• March 9, 2009

Report from the 16th Conference on Retroviruses and Opportunistic Infections

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

Our physician-editors weigh in on the most clinically relevant findings from the meeting.

• By Paul E. Sax, MD
• March 9, 2009

Lopinavir/r Is Superior to Nevirapine in Women Who Previously Received Single-Dose Nevirapine

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

In a large African trial described at CROI 2009, rates of both virologic failure and drug discontinuation were lower with lopinavir/r-based regimens than with nevirapine-based ones.

• By Judith Feinberg, MD
• March 9, 2009